Savara (SVRA) said late Wednesday it started a rolling submission of a biologics license application, or BLA, to the US Food and Drug Administration for Molbreevi, aimed at potentially treating autoimmune Pulmonary Alveolar Proteinosis, a rare lung disease.
The clinical-stage biopharmaceutical company said it plans to finalize the BLA submission by the end of Q1 2025 and intends to seek priority review.
Shares of Savara were up 0.3% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments